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S100 proteins interact with the transactivation domain and the C-terminus of p53. Further, S100B
has been shown to interact with MDM2, a central negative regulator of p53. Here, we show that
S100B bound directly to the folded N-terminal domain of MDM2 (residues 2-125) by size exclusion
chromatography and surface plasmon resonance experiments. This interaction with MDM2 (2-125)
is a general feature of S100 proteins; S100A1, S100A2, S100A4 and S100A6 also interact with MDM2
(2-125). These interactions with S100 proteins do not result in a ternary complex with MDM2 (2-125)
and p53. Instead, we observe the ability of a subset of S100 proteins to disrupt the extent of MDM2-
mediated p53 ubiquitylation in vitro.
Structured summary:
MINT-7905256: MDM2 (uniprotkb:Q00987) binds (MI:0407) to s100A6 (uniprotkb:P06703) by surface
plasmon resonance (MI:0107)
MINT-7905063:MDM2 (uniprotkb:Q00987) and s100A1 (uniprotkb:P23297) bind (MI:0407) by molecular
sieving (MI:0071)
MINT-7905376: s100A4 (uniprotkb:P26447) andMDM2 (uniprotkb:Q00987) physically interact (MI:0915)
by competition binding (MI:0405)
MINT-7905130: s100A6 (uniprotkb:P06703) and MDM2 (uniprotkb:Q00987) bind (MI:0407) by molecular
sieving (MI:0071)
MINT-7905207: s100A6 (uniprotkb:P06703) and p53 (uniprotkb:P04637) bind (MI:0407) by molecular
sieving (MI:0071)
MINT-7905043: s100B (uniprotkb:P04271) and MDM2 (uniprotkb:Q00987) bind (MI:0407) by molecular
sieving (MI:0071)
MINT-7905196: p53 (uniprotkb:P04637) and s100A4 (uniprotkb:P26447) bind (MI:0407) by molecular
sieving (MI:0071)
MINT-7905358: p53 (uniprotkb:P04637) and s100A4 (uniprotkb:P26447) physically interact (MI:0915) by
ﬂuorescence polarization spectroscopy (MI:0053)
MINT-7905220:MDM2 (uniprotkb:Q00987) binds (MI:0407) to s100B (uniprotkb:P04271) by surface plas-
mon resonance (MI:0107)
MINT-7905104: s100A4 (uniprotkb:P26447) andMDM2 (uniprotkb:Q00987) bind (MI:0407) by molecular
sieving (MI:0071)
MINT-7905229: MDM2 (uniprotkb:Q00987) binds (MI:0407) to s100A1 (uniprotkb:P23297) by surface
plasmon resonance (MI:0107)
MINT-7905317, MINT-7905162: s100B (uniprotkb:P04271) and p53 (uniprotkb:P04637) bind (MI:0407)
by molecular sieving (MI:0071)
MINT-7905238: MDM2 (uniprotkb:Q00987) binds (MI:0407) to s100A2 (uniprotkb:P29034) by surface
plasmon resonance (MI:0107)
MINT-7905174, MINT-7905308: s100A1 (uniprotkb:P23297) and p53 (uniprotkb:P04637) bind (MI:0407)
by molecular sieving (MI:0071)
MINT-7905247: MDM2 (uniprotkb:Q00987) binds (MI:0407) to s100A4 (uniprotkb:P26447) by surface
plasmon resonance (MI:0107)chemical Societies. Published by Elsevier B.V. All rights reserved.
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sieving (MI:0071)
MINT-7905142, MINT-7905326: MDM2 (uniprotkb:Q00987) and p53 (uniprotkb:P04637) bind (MI:0407)
by molecular sieving (MI:0071)
MINT-7905185, MINT-7905347: s100A2 (uniprotkb:P29034) and p53 (uniprotkb:P04637) bind (MI:0407)
by molecular sieving (MI:0071)
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S100 proteins are small acidic calcium-binding proteins. The
protein family consists of more than 25 members with intracellular
and extracellular functions [1]. The proteins usually form dimers.
Each monomer of S100 is composed of two EF-hand, Ca2+-binding
domains which are connected by a central hinge region. The high-
afﬁnity binding to calcium of the C-terminal classical EF-hand in-
duces a conformational change in the S100 proteins to expose a
hydrophobic binding site for target proteins. More than 50 target
proteins have been identiﬁed to interact with various S100 pro-
teins, including transcription factors, metabolic enzymes, kinases,
annexins or contractile proteins [2]. In general, most of these inter-
actions are dependent on calcium signalling, but a subset of inter-
actions is independent of Ca2+ activation [3].
S100 proteins are normally expressed in a tissue speciﬁc man-
ner and their up- or down-regulation has been associated with
numerous diseases including several types of cancer [4]. For
example, elevated serum levels of S100B have been found in mel-
anoma patients and have been associated with metastasis and a
poor therapy prognosis [4,5]. Animal studies showed that S100A4
is involved in the development of metastasis [6,7] and overexpres-
sion of S100A4 has been detected in various types of cancer,
including breast, pancreatic, colorectal, ovarian, prostate and lung
cancer. However, despite inferences to an important role in cancer
development, the mode of action of S100 proteins still remains
unclear.
Since there is an obvious link between cancer and S100 pro-
teins, the interaction of S100 family members with target proteins
also involved in cancer may help to understand the mode of action
of S100 proteins and their relevance in tumour development.
Among other targets, S100A1, S100A2, S100A4, S100A6 and
S100B interact with p53, one of the most important tumour sup-
pressors of the cell [8,9]. The interaction has been mapped to the
p53 (1-57) transactivation domain and the p53 (293-393) C-termi-
nus, which includes the tetramerisation domain [8–11]. However,
the effect of S100 proteins on p53 activity is not fully understood.
On the one hand, there are studies showing that S100B contributes
to nuclear accumulation and activation of p53 [12,13], on the other
hand, S100B is reported to inhibit p53 activity in transactivation
assays [14]. Further, S100A2 and S100A6 stimulate p53 activity
in transactivation assays [15,16].
One of the main negative regulators of p53 is the ubiquitin E3
ligase MDM2, which interacts with the N-terminal transactivation
domain of p53 and covalently links the proteasomal degradation
signal protein, ubiquitin, to lysine residues of p53 [17]. A GST-pull
down experiment shows that S100B interacts with MDM2 [18].
Isothermal titration calorimetry studies also show that S100B
interacts with a peptide derived from the N-terminal domain of
MDM2. Yet it remains unclear if S100 proteins can also bind in
the context of the full N-terminal domain of MDM2 [18].
Here, we investigated whether S100B and other S100 proteins
have the ability to interact with the full N-terminal domain of
MDM2. We found that S100A1, S100A2, S100A4, S100A6 andS100B interacted with MDM2 (2-125) in size exclusion chromatog-
raphy and multi-angle light scattering (SEC–MALS) and surface
plasmon resonance experiments but did not form a ternary com-
plex with MDM2 (2-125) and p53 (1-93). A ternary complex was
also absent between the tetramerization domain of p53, MDM2
and S100 proteins, S100B, S100A1, S100A2 and S100A4. When
evaluated in ubiquitylation assays, S100A2, S100A4 and S100A6
showed moderate levels of inhibition of MDM2 activity, providing
a possible mechanism for the stimulating effect of these S100 pro-
teins on p53 in vivo.2. Methods
2.1. Plasmids, protein expression and puriﬁcation
Plasmids used for the expression of untagged recombinant hu-
man S100A1, S100A2, S100A6 and S100B were as described [8,9].
The proteins were puriﬁed by ammonium sulphate precipitation,
hydrophobic interaction chromatography and gel ﬁltration.
S100A4 was expressed and puriﬁed via a His6-Tag and metal afﬁn-
ity chromatography and gel ﬁltration as described [9]. Human
MDM2 (2-125) was expressed as a GST-fusion protein and puriﬁed
as described [19]. The expression and puriﬁcation of human p53
(1-93) and p53 (1-393) has also been described elsewhere
[20,21]. p53 (313-393) L344P was constructed by PCR and cloned
into a pRSET vector. The protein was expressed as described [9].
2.2. Analytical size exclusion chromatography
Analytical gel ﬁltrations were performed using a GE Healthcare
Superdex™ 75 analytical gel ﬁltration column as described [10].
Hundred microliters of 25–100 lM proteins in physiological ionic
strength-buffer [9] (PIS-buffer) were injected. Multi-angle light
scattering (MALS) was detected on-line using a DAWN HELEOS™
(Wyatt Technology) and an Optilab™ rEX (Wyatt Technology).
The data were analysed using ASTRA™ software.
2.3. Surface plasmon resonance
Steady-state equilibrium experiments were performed with a
Biacore™ 2000 (GE Healthcare). A streptavidin-coated sensor Chip
SA (Ge Healthcare) was loaded with 100 ng biotinylated MDM2 (2-
125). The chip was then tested with different concentrations of
S100 proteins, 20 ll injections at a ﬂow rate of 5 ll/min. The bind-
ing experiments were performed in PIS-buffer and the bound S100
protein was washed off with 20 mM Tris pH 7.4, 200 mM NaCl and
1 mM EDTA. The binding was quantiﬁed using a two-site binding
model as described [9].
2.4. Biotinylation of MDM2 (2-125), ﬂuorescence anisotropy titrations
and ubiquitylation assay
See Supplementary data.
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3.1. S100 proteins interact with the N-terminal p53-binding domain of
MDM2
Previous studies indicated an interaction between S100B and a
peptide derived from the N-terminal domain of MDM2 [18]. Here
we investigated, whether S100B as well as other S100 proteins also
interact with the full N-terminal domain of MDM2. We initially
investigated the interaction by SEC–MALS, which has been shown
to be a powerful tool to study protein–protein interactions without
the use of a label or immobilization of one of the binding partners.
The elution proﬁles of S100 proteins together with MDM2 (2-125)0
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Fig. 1. S100 proteins interact with MDM2 (2-125) in SEC–MALS. Hundred microliters of
injected. When a mixture of proteins was injected (green), protein–protein interactions
components. The experiments were performed in PIS-buffer (A–C) or a calcium-free b
S100A4 + MDM2 (2-125), similar elution proﬁles were obtained with S100A1, S100A2 adisplayed peaks signiﬁcantly different in retention time (tr) and
weight-average molar mass (Mw) from the individual components
alone, indicating the presence of protein–protein interactions be-
tween S100 proteins and MDM2 (Fig. 1). The Mw of 31–35 kDa
across the peaks corresponded to a complex of one dimer of
S100 (20 kDa) and a monomer of MDM2 (2-125) (14.3 kDa)
for S100A1, S100A2, S100A4 and S100A6 (Table 1). For S100B, a
small shift in tr was observed corresponding to a Mw smaller than
calculated for the theoretical complex of a dimer of S100B and a
monomer MDM2 (2-125) (Table 1, Fig. 1B), indicating that the
interaction between S100B and MDM2 (2-125) was weaker than
that with the other S100 proteins (Fig. 1C). As a control, we showed
that MDM2 (2-125) interacts with p53 (1-93) in SEC–MALS, indi-0
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25 lMMDM2 (black), 25 lM p53 (1-93) (blue) and 50 lM S100 proteins (red) were
resulted in shifts in tr and Mw (horizontal line across the peak) from the individual
uffer (D and E). (A) MDM2 (2-125) + p53 (1-93), (B) S100B + MDM2 (2-125), (C)
nd S100A6, (D) S100B + MDM2 (2-125), (E) S100A4 + MDM2 (2-125).
Table 1
Mw of the dominant peak in the elution proﬁles of S100 proteins in complex with MDM2 as determined by MALS.
Mw (kDa)
— S100A1 S100A2 S100A4 S100A6 S100B
— 21.2 ± 1.0 22.8 ± 0.4 24.8 ± 0.1 20.5 ± 0.8 21.8 ± 0.7
MDM2 (2-125) 13.8 ± 0.1 31.0 ± 3.0 34.8 ± 1.0 33.0 ± 1.5 34.3 ± 4.0 24.0 ± 0.3
400
600
800
1000
1200
S100B
S100A1
R
U
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Further, the interaction of MDM2 (2-125) and S100 proteins was
dependent on calcium and no interaction could be detected in a
calcium-free buffer (Fig. 1D and 1E).
The interaction between S100 proteins and MDM2 (2-125) was
further analysed by surface plasmon resonance steady-state exper-
iments with immobilized biotinylated MDM2 (2-125). The binding
data ﬁtted best to a two-site binding model with a high-afﬁnity
binding site with dissociation constants (Kd) in the low lM range
and a low-afﬁnity binding site with dissociation constants
>100 lM (Table 2 and Fig. 2).
3.2. Interplay between p53, MDM2 and S100
S100 proteins not only bind to MDM2, but also interact with the
N-terminal transactivation domain and the C-terminus of p53
[10,11]. Here, we investigated whether S100, p53 and MDM2 can
form a ternary complex. The formation of such a ternary complex
with MDM2 and p53 has been suggested to be of physiological rel-
evance in the case of the histone acetyltransferase p300 [22]. We
initially studied the complex formation of p53 (1-93) and MDM2
(2-125) in the presence of S100 proteins by SEC–MALS, comparing
the elution proﬁles of the complexes S100/p53 (1-93), S100/MDM2
(2-125) and MDM2 (2-125)/p53 (1-93) with the elution proﬁles of
a mixture of S100, MDM2 and p53 (1-93). The tr and theMw across
the peaks did not correspond to a tight ternary complex of S100
proteins with p53 (1-93) and MDM2 (2-125), possessingMw values
much lower than theoretical mass of 45 kDa. The retention times
were more similar to the ones observed for the isolated complexes,
indicating that no ternary complex was formed for any of the S100
proteins tested (Fig. 3). A potential ternary complex was also eval-
uated with the C-terminus of p53 (313-393). The tetramerisation
domain of p53, especially in its monomeric form, has previously
been described as a binding site for S100B, S100A1 and S100A2
proteins [9]. To evaluate if MDM2 (2-125) and S100 proteins form
a ternary complex with p53 (313-393), the elution proﬁles of mix-
tures of S100 proteins, MDM2 (2-125) and a monomeric mutant of
p53, p53 (313-393) L344P were compared with the complexes of
p53 (313-393) L344P/MDM2 (2-125), S100/p53 (313-393) L344P
and S100/MDM2 (2-125) (Fig. 4 and Supplementary Figs. 1 and
2). The tr and Mw values were similar to the isolated complexes,
indicating no ternary complex formation between MDM2 (2-
125), p53 (313-393) L344P and S100 proteins S100B, S100A1 and
S100A2. Interestingly, according to the elution proﬁles of the com-
plexes, S100B formed a complex with p53 (313-393) L344P in the
presence of MDM2 (2-125) whereas S100A1 and S100A2 formed aTable 2
Afﬁnity of S100 proteins in a two-site binding model to biotinylated MDM2 (2-125) in
surface plasmon resonance.
Kd1 (lM) Kd2 (lM)
S100A1 3.8 ± 0.4 129 ± 16
S100A2 2.2 ± 0.4 >200
S100A4 2.5 ± 0.6 >200
S100A6 6.6 ± 0.7 >200
S100B 5.0 ± 1.6 240 ± 62complex with MDM2 (2-125) in the presence of p53 (313-393)
L344P.
We also studied the interplay between S100A4, MDM2 (2-125)
and the C-terminus of p53 by ﬂuorescence anisotropy, using the
ﬂuorescein-labelled monomeric mutant L344P of the tetramerisa-
tion domain p53 (325-355) L344P [9]. When a complex of
S100A4 and p53 (325-355) L344P peptide was titrated with
MDM2 (2-125) a decrease in anisotropy was observed, indicating
competition between MDM2 (2-125) and the p53-tetramerization
domain for the interaction with S100A4 and no ternary complex
formation (Supplementary Fig. 3).
3.3. S100 proteins inhibit MDM2-mediated ubiquitylation of p53
Given that S100 proteins make direct contacts with p53 and
MDM2, we examined the effect of S100 proteins on MDM2 ubiqui-
tylation of p53 in vitro. S100 proteins had a moderate effect on p53
oligo-ubiquitylation, with the largest inhibition of the extent of
ubiquitylation observed with S100A4 and S100A6 (Supplementary
Fig. 4 and Supplementary Table 1). A mild effect on ubiquitylation
was observed for S100A2. No changes in the extent of ubiquityla-
tion were observed for S100B and S100A1. Inhibition of ubiquityla-
tion was also calcium dependent (data not shown).
4. Discussion
The results presented here show that S100B interacts directly
with the p53-binding domain of MDM2 (2-125) in a calcium
dependent manner. Moreover, S100A1, S100A2, S100A4 and
S100A6 also interact with MDM2 (2-125), making the binding to0
200
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Fig. 2. S100 proteins interact with biotinylated MDM2 (2-125) in surface plasmon
resonance steady-state experiments. Immobilized biotinylated MDM2 (2-125) was
probed with S100A1 (orange) S100A2 (red) S100A4 (blue), S100A6 (green) and
S100B (black) at different concentrations and the resulting change in response units
were ﬁtted to a two-site binding model. The experiments were carried out in PIS-
buffer.
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Fig. 3. S100 proteins, p53 (1-93) and MDM2 (2-125) do not form a ternary complex in SEC–MALS. Hundred microliters of 50 lM S100 protein in the presence or absence of
25 lMMDM2 (2-125) and 25 lM p53 (1-93) in PIS were injected. The formation of a ternary complex was judged by differences in tr andMw in the elution proﬁle of a mixture
of S100/MDM2 (2-125)/p53 (1-93) (green) and the elution proﬁles of the protein complexes of S100/MDM2 (2-125) (black), S100/p53 (1-93) (blue) and MDM2 (2-125)/p53
(1-93) (red). (A) S100A1, (B) S100A2, (C) S100A4, (D) S100A6, (E) S100B.
J. van Dieck et al. / FEBS Letters 584 (2010) 3269–3274 3273MDM2 a general feature of S100 proteins. Additional structural
studies will be necessary to evaluate if the interaction is accompa-
nied by a conformational change within MDM2 (2-125) that liber-
ates the hypothesized target site (residues 25–43) within MDM2
required for S100 protein binding.
It is striking that we found here that S100 proteins interact with
MDM2 (2-125) since we have previously shown by various meth-
ods that S100 proteins also interact with the p53 transactivation
domain, which is the binding partner of MDM2 (2-125) [10,11].
It would be interesting to perform structural studies of the com-
plexes between S100 proteins, MDM2 (2-125) and the transactiva-
tion and tetramerization domains of p53 to compare binding
modes of the two substrates for S100 proteins. As these proteinsdo not form a ternary complex, it is likely that S100 proteins have
the ability to interfere with the interaction between MDM2 and
p53.
The potential relevance of these interactions is supported by the
observed inhibition of the extent of MDM2 ubiquitylation by
S100A2, S100A4 and S100A6 in vitro. Given that interactions exist
between multiple domains of p53, MDM2 and S100 proteins, sev-
eral sites may be simultaneously targeted during inhibition of
MDM2 function. Interestingly, the inhibition proﬁle correlates well
with the binding afﬁnities of S100 proteins for the p53 N-terminus,
suggesting that the interaction with p53 dominates the network of
interactions between these partners, as inferred by the observed
binding afﬁnities [10]. The inﬂuence of these S100 protein interac-
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Fig. 4. S100 proteins, p53 monomer (313-393) L344P and MDM2 (2-125) do not form a ternary complex in SEC–MALS. Ternary complex formation was determined by
examining differences between tr and Mw in the elution proﬁles of S100/MDM2 (2-125)/p53 (313-393) L344P (green) and the elution proﬁles of the protein mixtures S100/
MDM2 (2-125) (black), S100/p53 (313-393) L344P (blue) and MDM2 (2-125)/p53 (313-393) L344P (red). (A) S100A1, (B) S100B; 100 ll injections of 30 lM p53 (313-393)
L344P, 30 lM MDM2 (2-125) and/or 60 lM S100 protein were used in each experiment.
3274 J. van Dieck et al. / FEBS Letters 584 (2010) 3269–3274tions on p53 activity in vivo will be highly dependent on the con-
centrations of each partner, calcium and which S100 protein is
present. However, the interplay between S100 proteins, MDM2
and p53 may be physiologically relevant because S100 proteins
and MDM2 are often overexpressed in cancer [4,23]. The inhibition
of MDM2 activity could also explain the activating effects of
S100A2 and S100A6 on p53-mediated transcription in cellular as-
says [15,16]. Overall, we have identiﬁed an interaction between
S100 proteins and the N-terminal domain of MDM2 that does
not permit a ternary complex with p53 (1-93) or p53 (313-393)
L344P. Further, moderate inhibition of the extent of MDM2-medi-
ated ubiquitylation of p53 by S100A2, S100A4 and S100A6 may oc-
cur via several mechanisms that partially contribute to the
stimulatory effects of S100 proteins on p53 activity.
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